ICCC ImmuCell Corporation

MIXED Impact: 6/10 PRESS-RELEASE
Horizon days Filed Apr 8, 2026 Processed 2mo ago Wire GlobeNewswire
Press release: earnings
Latest settled — T+20d ⚠ clustered
ICCC ▲ +20.45% at T+20d
NEUTRAL call ✓ call won +20.45% · α vs SPY +12.88% · entry $7.19 → $8.66
Next anchor: T+60d in 23d
Last close $9.70 (close Jun 8) · +34.91% from $7.19 entry
Entry anchored
Apr 7, 12:16 PM ET
via Databento tick
T+1d
-1.53%
call -1.53% · α -1.47%
$7.08
settled 2mo ago
T+5d
+4.87%
call +4.87% · α +1.68%
$7.54
settled 8w ago
T+20d
+20.45%
call +20.45% · α +12.88%
$8.66
settled 5w ago
T+60d
call — · α —
in 23d

Price Chart

Loading chart...

Executive Summary

ImmuCell reported preliminary Q1 2026 sales of $10.4M, up 28.4% YoY, driven by a 38.5% surge in Tri-Shield® sales. International sales declined 30.2%, and EPS was a loss of $0.31. The company cited ongoing operational challenges from prior backlogs but expressed confidence in its growth strategy.

Actionable Insight

Traders should monitor the upcoming full financial release and conference call for clarity on gross margins, operating leverage, and whether domestic strength can offset international weakness; sustained Tri-Shield® momentum may support bullish sentiment if profitability improves.

Key Facts

  • Q1 2026 total sales: $10.4 million, up 28.4% YoY from $8.1 million
  • Domestic sales grew 35.7% to $9.7 million
  • International sales fell 30.2% to $0.6 million
  • Tri-Shield® sales increased 38.5% to $7.9 million
  • Dual Force® & Other sales up 4.4% to $2.5 million
  • EPS reported as -$0.31, though no consensus estimate was available
  • Company hosted a conference call on May 15, 2026, to discuss unaudited results

Financial Impact

Revenue increased by $2.3 million YoY, but international segment declined sharply; net income not disclosed but EPS loss of $0.31 indicates continued unprofitability

revenueepsinternational salesdomestic sales

Risk Factors

  • International sales declined significantly (-30.2%), raising concerns about global demand or distribution
  • Ongoing backorder recovery may distort future growth comparisons
  • EPS remains negative, indicating continued losses despite revenue growth

Market Snapshot

Exchange
Nasdaq
Sector
In Vitro & In Vivo Diagnostic Substances

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3270500
5 reports for ICCC
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for ICCC — sortable, filterable
Type Now
May 8, 2026
4w ago
8-K
BULLISH ★ 4/10
$8.45 $9.91▲ +17.28%▲ +17.36%$9.70 (+14.79%)
Apr 8, 2026
8w ago
8-K
BULLISH ★ 7/10
$7.19 $7.54▲ +4.87%▲ +1.68%$9.70 (+34.91%)
Apr 8, 2026
8w ago
Press Release
MIXED ★ 6/10
$7.19 $7.54▲ +4.87%▲ +1.68%$9.70 (+34.91%)
Mar 4, 2026
13w ago
8-K
MIXED ★ 6/10
$6.35 $6.63▲ +4.41%▲ +6.65%$9.70 (+52.76%)
Mar 4, 2026
13w ago
Press Release
MIXED ★ 6/10
$6.35 $6.63▲ +4.41%▲ +6.65%$9.70 (+52.76%)
Showing 5 of 5

US Market Status

Market Closed — Opens in 6h 58m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access